Investors Purchase Large Volume of Compass Pathways Call Options (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw unusually large options trading on Monday. Stock investors purchased 24,075 call options on the company. This represents an increase of 335% compared to the average daily volume of 5,530 call options.

Compass Pathways Stock Up 1.6%

Shares of NASDAQ:CMPS traded up $0.20 during mid-day trading on Monday, hitting $12.72. 2,312,301 shares of the company traded hands, compared to its average volume of 3,608,655. The stock has a 50-day moving average price of $10.22 and a two-hundred day moving average price of $7.86. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $14.76. The stock has a market cap of $1.72 billion, a P/E ratio of -4.04 and a beta of 2.50. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. On average, equities research analysts forecast that Compass Pathways will post -1.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of recent analyst reports. TD Cowen reissued a “buy” rating on shares of Compass Pathways in a research note on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Canaccord Genuity Group lowered their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, March 26th. Raymond James Financial reissued a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Finally, Wolfe Research started coverage on Compass Pathways in a report on Friday, May 22nd. They set an “outperform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $21.36.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMPS. Seven Fleet Capital Management LP boosted its position in Compass Pathways by 295.1% during the first quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock valued at $874,000 after buying an additional 118,021 shares during the period. Parallel Advisors LLC increased its holdings in shares of Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after buying an additional 7,183 shares during the period. Vivo Capital LLC bought a new stake in shares of Compass Pathways in the 1st quarter valued at about $1,106,000. Bank of America Corp DE boosted its holdings in Compass Pathways by 43.8% during the 1st quarter. Bank of America Corp DE now owns 32,332 shares of the company’s stock valued at $179,000 after acquiring an additional 9,853 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after acquiring an additional 1,920 shares during the period. 46.19% of the stock is owned by institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.